Chondrolectin mediates growth cone interactions of motor axons with an intermediate target

Citation for published version:

Digital Object Identifier (DOI):

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Journal of Neuroscience

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Development/Plasticity/Repair

Chondrolectin Mediates Growth Cone Interactions of Motor Axons with an Intermediate Target

Zhen Zhong, 1 Jochen Ohnmacht, 1 Michell M. Reimer, 1,2 Ingolf Bach, 3,4 Thomas Becker, 1,* and Catherina G. Becker 1*
1Centre for Neuroregeneration, University of Edinburgh, Edinburgh EH16 4SB, United Kingdom, 2Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, United Kingdom, and 3Program in Gene Function and Expression and 4Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605

The C-type lectin chondrolectin (chodl) represents one of the major gene products dysregulated in spinal muscular atrophy models in mice. However, to date, no function has been determined for the gene. We have identified chodl and other novel genes potentially involved in motor axon differentiation, by expression profiling of transgenically labeled motor neurons in embryonic zebrafish. To enrich the profile for genes involved in differentiation of peripheral motor axons, we inhibited the function of LIM-HDs (LIM homeodomain factors) by overexpression of a dominant-negative cofactor, thereby rendering labeled axons unable to grow out of the spinal cord. Importantly, labeled cells still exhibited axon growth and most cells retained markers of motor neuron identity. Functional tests of chodl, by overexpression and knockdown, confirm crucial functions of this gene for motor axon growth in vivo. Indeed, knockdown of chodl induces arrest or stalling of motor axon growth at the horizontal myoseptum, an intermediate target and navigational choice point, and reduced muscle innervation at later developmental stages. This phenotype is rescued by chodl overexpression, suggesting that correct expression levels of chodl are important for interactions of growth cones of motor axons with the horizontal myoseptum. Combined, these results identify upstream regulators and downstream functions of chodl during motor axon growth.

Introduction

Motor axons make complex pathway decisions during their growth to their eventual muscle targets (Landmesser, 2001; Guthrie, 2007). At the same time, neurodegenerative diseases of the spinal cord often affect motor neurons. Recognition molecules, necessary for axonal navigation, have been implicated in the disease process (Schmidt et al., 2009). Thus, to identify potential therapeutic targets, there is a need to better understand axonal differentiation of motor neurons and the molecules involved (Bonanomi and Pfaff, 2010).

The zebrafish is ideally suited for such studies because of the unique development of primary motor neurons in the trunk that allows functional analyses of development at the single-cell level (Lewis and Eisen, 2003). In each hemisection of the trunk, three to four primary motor neurons send out pioneer axons on a joint trajectory to the horizontal myoseptum, an intermediate target.

From here, the axon of the caudal primary motor neuron (CaP) continues to grow ventrally, the middle primary motor neuron (MiP) forms a dorsal collateral from a more dorsal position along the axon, and the rostral primary motor neuron (RoP) grows its axon laterally. The CaP axon is the first to grow out, followed by MiP and RoP (Eisen et al., 1986; Myers et al., 1986).

A number of factors have been found that specifically affect interactions of growing motor axons with the horizontal myoseptum choice point (Bernhardt and Schachner, 2000; Rodino-Klapac and Beattie, 2004; Zhang et al., 2004; Schweitzer et al., 2005; Schneider and Granato, 2006; Hilario et al., 2010). Many of these factors are either extracellular matrix (ECM) components at the horizontal myoseptum or genes that modify the ECM. However, relatively little is known about the potential receptors on the axons.

Motor neuron identity, as well as axonal pathfinding, depend on LIM-domain containing transcription factors [LIM homeodomain factors (LIM-HDs)] in vertebrates (Tsushida et al., 1994; Pfaff et al., 1996; Bhati et al., 2008), including zebrafish (Inoue et al., 1994; Appel et al., 1995; Tokumoto et al., 1995; Hutchinson and Eisen, 2006; Hutchinson et al., 2007). LIM-HDs control the expression of axon pathfinding genes in motor neurons (Kania and Jessell, 2003) and sensory neurons (Miya-shita et al., 2004; Yeo et al., 2004) and function in complexes with cofactors, such as CLIM (also known as NLI and Ldb) (Lee and Pfaff, 2003; Gungor et al., 2007). Overexpression of a dominant-negative form of CLIM in zebrafish (DN-CLIM) prevents motor neurons from forming correct projections (Segawa et al., 2001; Becker et al., 2002). Indeed, motor neurons in the ventral spinal cord that overexpress DN-CLIM can...
still grow axons, but only inside the spinal cord (Segawa et al., 2001; Zhong et al., 2011).

Here, we use these neurons for expression profiling to find genes involved in motor axon navigation. We identify the motor neuron-specific C-type lectin gene chordrolectin (chodi), previously found to be dysregulated in mouse spinal muscular atrophy (SMA) models (Zhang et al., 2008; Bäumer et al., 2009), as an important regulator of motor axon/choice point interactions during development.

Materials and Methods

Animals. All fish are kept and bred in our laboratory fish facility according to standard methods (Westerfield, 2000), and all experimental procedures have been approved by the British Home Office. We used wild-type (wik) and Tg(mnx1:GFP)m2/O (Flanagan-Steeet et al., 2005) and Tg(vsx1:GFP)m5/ (Kimura et al., 2008) embryos of either sex. For simplicity, Tg(mnx1:GFP)m2 is designated HB9:GFP throughout this manuscript.

Gene knockdown. We purchased splice site-directed morpholinos to chodi (MO1: exon 2–intron 2 splice site, CTGAA; MO2: intron 1–exon 2 splice site, CTGACCTGGAGAGACAAAATTCCACA), a start codon directed morpholino (MO3: CGATCTCGTGTGGTCCTGGTACGTCGTTCCCTGGTACGTC), and standard control morpholino from Gene Tools. For injections, rhodamine dextran (0.8%; Mw = 10 × 10^6) was added to morpholino solutions. A glass micropipette was filled with morpholino solution. A volume of 0.5 nl per egg (one- to four-cell stage) was injected as described previously (Feldner et al., 2007).

Generally, the morpholino concentration was 1 mM, if not stated otherwise. Control morpholino injections were performed with every experiment to avoid any influence of the morpholino. For rescue and synergy experiments, the embryos receiving specific morpholinos, to avoid any influence of the morpholino, were injected with every experiment to avoid any influence of the morpholino.

Immunohistochemistry. Here, we use these neurons for expression profiling to find genes involved in motor axon navigation. We identify the motor neuron-specific C-type lectin gene chordrolectin (chodi), previously found to be dysregulated in mouse spinal muscular atrophy (SMA) models (Zhang et al., 2008; Bämer et al., 2009), as an important regulator of motor axon/choice point interactions during development.

Materials and Methods

Animals. All fish are kept and bred in our laboratory fish facility according to standard methods (Westerfield, 2000), and all experimental procedures have been approved by the British Home Office. We used wild-type (wik) and Tg(mnx1:GFP)m2/O (Flanagan-Steeet et al., 2005) and Tg(vsx1:GFP)m5/ (Kimura et al., 2008) embryos of either sex. For simplicity, Tg(mnx1:GFP)m2 is designated HB9:GFP throughout this manuscript.

Gene knockdown. We purchased splice site-directed morpholinos to chodi (MO1: exon 2–intron 2 splice site, CTGAA; MO2: intron 1–exon 2 splice site, CTGACCTGGAGAGACAAAATTCCACA), a start codon directed morpholino (MO3: CGATCTCGTGTGGTCCTGGTACGTCGTTCCCTGGTACGTC), and standard control morpholino from Gene Tools. For injections, rhodamine dextran (0.8%; Mw = 10 × 10^6) was added to morpholino solutions. A glass micropipette was filled with morpholino solution. A volume of 0.5 nl per egg (one- to four-cell stage) was injected as described previously (Feldner et al., 2007).

Generally, the morpholino concentration was 1 mM, if not stated otherwise. Control morpholino injections were performed with every experiment to avoid any influence of the morpholino. For rescue and synergy experiments, the embryos receiving specific morpholinos, to avoid any influence of the morpholino, were injected with every experiment to avoid any influence of the morpholino.

Immunohistochemistry. Here, we use these neurons for expression profiling to find genes involved in motor axon navigation. We identify the motor neuron-specific C-type lectin gene chordrolectin (chodi), previously found to be dysregulated in mouse spinal muscular atrophy (SMA) models (Zhang et al., 2008; Bämer et al., 2009), as an important regulator of motor axon/choice point interactions during development.

Materials and Methods

Animals. All fish are kept and bred in our laboratory fish facility according to standard methods (Westerfield, 2000), and all experimental procedures have been approved by the British Home Office. We used wild-type (wik) and Tg(mnx1:GFP)m2/O (Flanagan-Steeet et al., 2005) and Tg(vsx1:GFP)m5/ (Kimura et al., 2008) embryos of either sex. For simplicity, Tg(mnx1:GFP)m2 is designated HB9:GFP throughout this manuscript.

Gene knockdown. We purchased splice site-directed morpholinos to chodi (MO1: exon 2–intron 2 splice site, CTGAA; MO2: intron 1–exon 2 splice site, CTGACCTGGAGAGACAAAATTCCACA), a start codon directed morpholino (MO3: CGATCTCGTGTGGTCCTGGTACGTCGTTCCCTGGTACGTC), and standard control morpholino from Gene Tools. For injections, rhodamine dextran (0.8%; Mw = 10 × 10^6) was added to morpholino solutions. A glass micropipette was filled with morpholino solution. A volume of 0.5 nl per egg (one- to four-cell stage) was injected as described previously (Feldner et al., 2007).

Generally, the morpholino concentration was 1 mM, if not stated otherwise. Control morpholino injections were performed with every experiment to avoid any influence of the morpholino. For rescue and synergy experiments, the embryos receiving specific morpholinos, to avoid any influence of the morpholino, were injected with every experiment to avoid any influence of the morpholino.

Immunohistochemistry. Here, we use these neurons for expression profiling to find genes involved in motor axon navigation. We identify the motor neuron-specific C-type lectin gene chordrolectin (chodi), previously found to be dysregulated in mouse spinal muscular atrophy (SMA) models (Zhang et al., 2008; Bämer et al., 2009), as an important regulator of motor axon/choice point interactions during development.
nal edge of the ventral myotome. Additional categories were as follows: shorter than the position of the horizontal myoseptum (HM−), at the horizontal myoseptum (HM), or grown beyond the horizontal myoseptum but still shorter than wild-type length (HM+/H11002). The horizontal myoseptum was either identified by 4D9 immunoreactivity (znplabeled preparations) or by the characteristic thickening of the CaP axon at the horizontal myoseptum (HB9:GFP transgenic embryos). The observer was always blinded to the treatment of the embryos.

Data are presented as mean, and error bars indicate the SEM. Groups were compared by Mann–Whitney U test (for two groups), one-way ANOVA, or two-way ANOVA followed by the Holm–Sidac post hoc test (SigmaStat 3.5) for multiple comparisons.

Results
To identify new genes that are involved in motor axon growth, we decided to use expression profiling of transgenically labeled primary trunk motor neurons (Fig. 1A) in which LIM-HD signaling is compromised. LIM-HD transcription factors are pivotal regulators of motor neuron development during embryogenesis of many species (Tsuchida et al., 1994; Pfaff et al., 1996; Bhati et al., 2008). To exert these functions, LIM-HDs require the association of CLIM cofactors (Lee and Pfaff, 2003). Inhibition of LIM-HDs was achieved via overexpression of a DN-CLIM protein. While lacking motifs that mediate interactions with other classes of proteins, DN-CLIM only contains the LIM-interaction domain (LID) and a nuclear localization signal, thus specifically targeting LIM-HD transcription factors (Segawa et al., 2001; Güngör et al., 2007) (Fig. 1B). Overexpression of DN-CLIM in HB9:GFP transgenic zebrafish resulted in axons emerging from GFP-positive neurons, but these axons grew along the ventral edge of the spinal cord instead of exiting it (Fig. 1C) (Segawa et al., 2001; Zhong et al., 2011). The presence of GFP-expressing neurons in these embryos indicated that the HB9 promoter fragment used to generate this fish was still active and suggested that GFP+ cells might have retained motor neuron characteristics. Hence, expression profiles from motor neurons versus GFP+ cells in DN-CLIM-treated embryos could be enriched for genes that are involved specifically in motor axon pathfinding and not in cell fate decisions or axon growth per se. A similar approach has led to the identification of genes involved in formation of the midbrain–hindbrain boundary downstream of LIM-HDs (Hirate et al., 2001). However, transfating of motor neurons into interneuron cell types has been described after compromising LIM-HD signaling (Segawa et al., 2001), warranting further investigations into the identity of HB9:GFP+ cells in control and DN-CLIM-treated animals.

Identity of HB9:GFP+ cells in DN-CLIM-injected embryos
In control embryos, the HB9:GFP transgene was clearly expressed in motor neurons in the ventral spinal cord with axons exiting the spinal cord. Furthermore, HB9 immunoreactivity was
found in 61% of HB9:GFP+ cells, and 60% of the cells showed immunoreactivity for Islet-1/-2 (Fig. 2A–D). Some of the GFP+ cells in each hemisegment were positive for ChAT, indicating a mature motor neuron phenotype for some of the HB9:GFP+ motor neurons (Fig. 2E,F). The cells that were not labeled for HB9 or Islet-1/-2 antibodies displayed generally weaker GFP expression. To determine whether these cells could be interneurons, we used double labeling with markers of interneurons. However, *nkx1.2lb* mRNA (Bae et al., 2004), Chx10 protein (Kimura et al., 2008), Pax2 protein (Batista and Lewis, 2008), and GABA (Segawa et al., 2001) revealed no or little overlap with GFP labeling (Fig. 3). Thus, the majority of HB9:GFP+ cells were likely motor neurons on the basis of axonal projections out of the spinal cord and expression of motor neuron markers (HB9; Islet-1/-2). Some cells that expressed lower levels of GFP might have been interneurons of undetermined identity or developing motor neurons in which incipient transgene expression was detectable, but immunohistochemistry was not sufficiently sensitive to detect low levels of endogenous protein.

In DN-CLIM-injected embryos, 29% fewer HB9:GFP+ cells were observed (control: 25.5 ± 1.59 cells, n = 6 embryos; DN-CLIM: 18.2 ± 0.65 cells, n = 6 embryos; p < 0.01). This could
indicate that some cells adopted a different fate. However, these cells would not skew a further analysis of gene expression, as they would not be sorted into the pool of fluorescent cells. The cells that still expressed GFP also retained immunoreactivity for the motor neuron markers HB9 (56%) and Islet-1/2 (56%) both to an extent that was not significantly different from controls (Fig. 2A–D). This is consistent with the hypothesis that fate changes of GFP+ cells were rare. Single HB9:GFP/H11001 cells were observable in

Figure 3. DN-CLIM treatment differentially affects interneuron marker expression in HB9:GFP+ cells. Trunk views are shown; for orientation, see Figure 1A. Double/triple-labeled cells are indicated by arrowheads. A, B, Double labeling of Islet-1/2 and GABA in HB9:GFP+ cells indicates a small, but significant increase in HB9:GFP/GABA and Islet-1/2/GABA double-labeled cells after DN-CLIM treatment. The arrow indicates a cell that is only labeled by the transgene and GABA antibody; the open arrow indicates a cell that is only labeled by Islet-1/2 and GABA antibodies. The dorsal location of this cell suggests interneuron identity. C, D, The proportion of HB9:GFP+ cells that are colabeled with Chox10 immunolabeling remains very small after DN-CLIM treatment. E, F, There is no apparent overlap of nkx1.2lb mRNA, nor Pax2 immunoreactivity, and HB9:GFP transgene in control and DN-CLIM-treated animals. *p < 0.05 (one-sided); **p < 0.01. Scale bar, 50 μm. Error bars indicate SEM.
the ventral spinal cord that could be colabeled with HB9 or Islet-1/-2 antibodies and grew an axon within the spinal cord of DN-CLIM-treated embryos (Fig. 2A,C), indicating that motor neuron-like cells still grew (intraspinal) axon. However, the proportion of segments that contained motor neurons expressing the mature marker ChAT was reduced by 65% (Fig. 2E,F), suggesting that motor neuron maturation was attenuated by DN-CLIM.

After DN-CLIM injection, the proportion of HB9:GFP cells that were colabeled by Chx10 antibodies remained unchanged (4% in controls and 5% in DN-CLIM-treated embryos), suggesting that HB9:GFP + cells did not change their fate into interneurons that express Chx10 (Fig. 3C,D). Moreover, HB9:GFP + cell did not acquire expression of ntx1.2b mRNA (Fig. 3E) or Pax2 immunoreactivity after DN-CLIM injection (Fig. 3F). However, it has previously been shown that Islet-2 + motor neurons acquire the interneuron marker GABA when cofactor interactions of LIM-HDs are disrupted (Segawa et al., 2001). Therefore, we quantified coexpression in triple-labeling studies of HB9:GFP, Islet-1/-2, and GABA. Indeed, the proportion of Islet-1/-2 + cells in the ventral spinal cord that were also GABA + was significantly increased from 1% in controls to 14% in DN-CLIM-treated embryos. Likewise, the proportion of HB9:GFP + cells that were also GABA + was significantly increased from 2 to 12% (Fig. 3A,B). In summary, the majority of HB9:GFP + cells retained motor neuron identity to some extent, as indicated by HB9 and Islet-1/-2 immunoreactivity, whereas full maturation into ChAT + motor neurons was attenuated and some HB9:GFP + cells acquired interneuron characteristics (i.e., GABA immunoreactivity).

Expression profiling reveals motor neuron expressed genes that are downstream of LIM-HDs

Since most HB9:GFP + cells in DN-CLIM-injected embryos retained at least some characteristics of motor neurons, we next used DN-CLIM-injected versus uninjected HB9:GFP transgenic embryos for successful FACS of HB9:GFP cells (Fig. 4A) followed by expression profiling. Thus, we obtained a list of >160 sequences that were downregulated at least twofold in GFP + cells in DN-CLIM-injected embryos compared with GFP + motor neurons in uninjected embryos. Comparing expression of GFP + motor neurons with GFP + cells in wild-type embryos from embryonic trunks and tails yielded >2100 at least twofold overrepresented sequences in HB9:GFP + motor neurons (data not shown). The intersection of these two lists contained 28 sequences that were both downregulated after DN-CLIM treatment and overrepresented in GFP + cells of the trunk and tail of uninjected embryos (Table 1). Among the top 10 regulated genes, we found chodl, tac1, and calca to be expressed in clusters in the
ventral spinal cord in the position of motor neurons, using the available online expression patterns (ZFIN.org). In situ hybridization for these genes in HB9:GFP transgenic embryos at 24 hpf confirmed expression in motor neurons with axons growing out of the spinal cord and absence of a signal in DN-CLIM-injected embryos (Fig. 4B–H). These results showed that expression of chodl, tac1, and calca is downstream of LIM-HDs in motor neurons and validated these screen results.

**chodl, tac1, and calca regulation could be relatively proximal to the LIM-HD regulatory network or their lack of expression after DN-CLIM overexpression could be a consequence of axons not exiting the spinal cord and therefore not receiving inductive signals. To determine whether such inductive signals could play a role, we determined the onset of chodl signals. To determine whether such inductive signals could play a role, we determined the onset of chodl signals.**

**Table 1. Sequences that are downregulated after DN-CLIM treatment and enriched in HB9:GFP + neurons of wild-type embryos (sorted by fold downregulation after DN-CLIM treatment)**

<table>
<thead>
<tr>
<th>Fold downregulation after DN-CLIM treatment</th>
<th>Fold higher in HB9:GFP + versus HB9:GFP -</th>
<th>Sequence designation on gene array</th>
<th>Gene name</th>
</tr>
</thead>
<tbody>
<tr>
<td>−0.4091</td>
<td>3.0531</td>
<td>vxa2</td>
<td>vxa2</td>
</tr>
<tr>
<td>−3.374</td>
<td>18.8099</td>
<td>nklx1.2b</td>
<td>nklx1.2b</td>
</tr>
<tr>
<td>−3.2371</td>
<td>8.68663</td>
<td>Tc285423</td>
<td>chodl</td>
</tr>
<tr>
<td>−3.127</td>
<td>2.79665</td>
<td>fli13639</td>
<td>36k</td>
</tr>
<tr>
<td>−2.9492</td>
<td>7.22032</td>
<td>tal2</td>
<td>tal2</td>
</tr>
<tr>
<td>−2.8507</td>
<td>8.51966</td>
<td>zgc92886</td>
<td>calca</td>
</tr>
<tr>
<td>−2.8159</td>
<td>3.47611</td>
<td>wufrk57906</td>
<td></td>
</tr>
<tr>
<td>−2.7056</td>
<td>7.35989</td>
<td>hdbd9</td>
<td>mm1</td>
</tr>
<tr>
<td>−2.6079</td>
<td>34.453</td>
<td>Bco83533</td>
<td>tac1</td>
</tr>
<tr>
<td>−2.5928</td>
<td>12.2849</td>
<td>sld6a5</td>
<td>gtyf2</td>
</tr>
<tr>
<td>−2.5804</td>
<td>7.01896</td>
<td>Bib64161</td>
<td>syt6</td>
</tr>
<tr>
<td>−2.5822</td>
<td>2.78151</td>
<td>Tc291825</td>
<td>lmo1</td>
</tr>
<tr>
<td>−2.5659</td>
<td>2.06127</td>
<td>try</td>
<td>try</td>
</tr>
<tr>
<td>−2.4778</td>
<td>2.22156</td>
<td>Tc299721</td>
<td>zgc16547</td>
</tr>
<tr>
<td>−2.4615</td>
<td>7.0457</td>
<td>Bja7657</td>
<td></td>
</tr>
<tr>
<td>−2.3383</td>
<td>2.99083</td>
<td>Ensdart000000113302</td>
<td>slc6a17</td>
</tr>
<tr>
<td>−2.3125</td>
<td>2.26726</td>
<td>Ck937088</td>
<td></td>
</tr>
<tr>
<td>−2.2928</td>
<td>10.3374</td>
<td>Ck705301</td>
<td>st18</td>
</tr>
<tr>
<td>−2.2926</td>
<td>2.30332</td>
<td>Tpbg1</td>
<td></td>
</tr>
<tr>
<td>−2.2236</td>
<td>7.93957</td>
<td>Ensdart000000002223</td>
<td></td>
</tr>
<tr>
<td>−2.1145</td>
<td>13.2978</td>
<td>zgc101108</td>
<td>nph1</td>
</tr>
<tr>
<td>−2.1115</td>
<td>2.11138</td>
<td>zgc92208</td>
<td>mlt10</td>
</tr>
<tr>
<td>−2.0953</td>
<td>2.05984</td>
<td>Bco55562</td>
<td>tado2</td>
</tr>
<tr>
<td>−2.0502</td>
<td>26.233</td>
<td>gad1</td>
<td>gad1</td>
</tr>
<tr>
<td>−2.0441</td>
<td>3.32192</td>
<td>tk1</td>
<td>tk1</td>
</tr>
<tr>
<td>−2.0315</td>
<td>3.02975</td>
<td>Bib40491</td>
<td></td>
</tr>
<tr>
<td>−2.0157</td>
<td>2.3796</td>
<td>Al725137</td>
<td>ei3a</td>
</tr>
<tr>
<td>−2.0045</td>
<td>2.13384</td>
<td>Tc273590</td>
<td>chodl</td>
</tr>
</tbody>
</table>

### chodl

**chodl is a C-type lectin gene expressed in developing motor neurons**

Because chodl has been implicated in motor neuron disease, but its function has not been elucidated (Zhang et al., 2008; Bäumer et al., 2009), we focused our further analysis on this gene. Cloning of a zebrafish cDNA encoding chodl in full length revealed a sequence coding for a predicted protein of 296 aa with a signal peptide (amino acids 1–20), a C-type lectin domain (amino acids 30–187), and a transmembrane domain (amino acids 238–260), suggesting cell surface localization (Fig. 5A). Comparisons with other vertebrate groups revealed a high degree of overall conservation (e.g., 94% identity with *Xenopus* and chicken and 92% with mouse and human; Fig. 5B).

Whole-mount in situ hybridization indicated no expression of chodl at 8 and 10 hpf, but at 12 hpf expression was detected in lateral cells of the head and ventral cells in the midtrunk region, consistent with the positions of the trigeminal ganglia and motor neurons, respectively. At 20 hpf, expression was detected in cranial ganglia, motor neurons, and a row of cells in the dorsal spinal cord. By 24 hpf, this expression was downregulated again, and in the spinal cord expression of chodl appeared to be restricted to HB9:GFP + motor neurons, many of which had axons that left the spinal cord. Vsx1 is a marker for interneurons that emerge from the ventricular zone adjacent and directly dorsal to motor neurons. In transgenic fish, in which GFP expression is driven by the vxs1 promoter (Kimura et al., 2008), no overlap of GFP labeling with chodl mRNA expression was observed at 24 hpf (data not shown), lending further support to expression of chodl in the trunk mainly in motor neurons. In addition, cranial ganglia and neurons in the forebrain were labeled by the probe (Fig. 5C–H). Thus chodl expression is restricted to specific cells types in the nervous system and is expressed in primary motor neurons from early stages of their differentiation to at least 24 hpf.

**chodl is important for motor axon growth**

To determine the function of chodl, we designed two splice-blocking morpholinos, both targeting exon 2. MO1 (1 mM), targeting the exon 2/intron 2 boundary, and MO2 (1 mM), targeting the intron 1/exon 2 boundary, modestly reduced the intensity of the wild-type PCR band in injected embryos at 24 hpf. Combining the two morpholinos at one-half the concentration each (0.5 mM) had a more profound reducing effect on the wild-type band and produced an extra band, potentially due to a cryptic splice site being revealed (Draper et al., 2001) (Fig. 6A). Sequencing this ectopic band indicated precise excision of exon 2, leading to premature stop codons, such that it is unlikely that the aberrantly spliced message led to translation of functional protein. Using another primer combination, in which the upstream primer was located in intron 2, 49 bp upstream of exon 3, amplified a transcript when MO2 was used. This transcript was much more abundant, when MO1 and MO2 were injected together. Sequencing of this band revealed that it indeed contained intronic sequences. This aberrant splice product could potentially interfere with chodl gene function.

The differences in the degrees of alterations of the wild-type transcript by these different treatments were reflected in the penetrance of the phenotype. MO1 (1 mM) alone had no significant effect on motor axon growth at 24 hpf, and MO2 (1 mM) led to

into the muscle periphery. These data indicated that chodl regulation is most likely to be proximal to the LIM-HD network, whereas extrinsic inductive signals could play a more prominent role for expression of tac1 and calca.
only a small (13%) but significant proportion of motor axons that were shorter than in control morpholino-injected embryos (2.4%). However, the combination of MO1 and MO2 at one-half the concentration each (0.5 mM) led to a synergistic and significant effect of 34% shorter motor axons, supporting that knockdown of *chodl* impaired motor axon growth.

Since even the combination of MO1 and MO2 did not fully reduce the transcription of wild-type mRNA, we designed a translation-blocking morpholino, MO3. This morpholino showed a significant and dose-dependent shortening of axons with a very high penetrance of up to 95% of motor axons (Fig. 6B,C). This morpholino was used in all following experiments.

To determine whether morpholino treatment could nonspecifically retard general development, we analyzed the segmental position of the primordium of the lateral line nerve, because this...
Knockdown of chodl leads to shorter motor axons and reduced innervation of myotomes at later developmental stages.

A, A primer pair located in exons 1 (primer 1) and 7 yields a weaker wild-type band for chodl after application of two splice-site directed morpholinos in PCR. Coapplication of the morpholinos additionally leads to an ectopic band (MO1, 1 mM; MO2, 1 mM; MO1 plus MO2, 0.5 mM each). Using a primer pair in intron 2 (primer 2) and exon 7 reveals a transcript that includes intronic sequences after treatment with MO2. In embryos injected with both morpholinos, this abnormal transcript is amplified much more strongly.

B, Quantification of axonal aberrations shows different magnitudes of effects on CaP axons that depend on morpholino combinations and concentrations (numbers of embryos are given on top of bars). C, Examples of morpholino actions on znp-1-labeled motor axons at 24 hpf are shown (orientation as in Fig. 1A). Shorter axons are indicated by arrowheads (control, 1 mM control morpholino; MO1 plus MO2, 0.5 mM each; MO3, 1 mM). D, Lateral trunk views at 33 hpf are shown; orientation as in Figure 1A. Many znp-1-labeled MiP axons do not reach the level of the dorsal border of the spinal cord in morphants. MiPs of normal length are pointed out by arrows. Shorter CaP axons in (Figure legend continues.)
nerve grows continually from rostral to caudal along the trunk and is, therefore, also used to stage embryonic development (Kimmel et al., 1995). Trunk segment 4.8 ± 0.18 was reached in control morpholino-treated embryos and trunk segment 4.4 ± 0.15 in chodl morphants at 24 hpf (n > 40 for each group; p > 0.05). Thus, the position of the lateral line primordium in morphants did not show a statistically significant difference from controls. Moreover, the shape and size of trunk segments was not altered compared with control morpholino-injected embryos (data not shown). In our hands (Feldner et al., 2005, 2007; Schweitzer et al., 2005), a number of specific and control morpholinos have never produced the present phenotype, which consists of unbranched shorter motor axons. Thus, a number of observations strongly suggest that morpholino effects were specific (Eisen and Smith, 2008): (1) different morpholinos elicited the same very specific phenotype; (2) they acted synergistically; (3) general morphology and developmental progress were undisturbed; (4) importantly, morpholino effects were rescued by mRNA overexpression (see below).

To elucidate whether MiP axones were also affected by chodl knockdown, we determined the trajectories of MiP axons in whole-mounted znp-1-labeled embryos at 33 hpf. Almost all (98%) dorsally growing wild-type axons reached or exceeded the dorsal edge of the medially located spinal cord, whereas significantly fewer axons (54%) reached the dorsal edge of the spinal cord in morphants (Fig. 6D,E). As a control, we measured the thickness of the spinal cord, which could have skewed our quantification. Morpholino treatment did not affect the thickness of the spinal cord at 33 hpf (uninjected control, 49.3 ± 1.15 μm, n = 6; morphant, 49.8 ± 1.66 μm, n = 6; p = 0.8). Thus, MiP axon growth was impaired. This suggests that chodl is important for CaP as well as MiP axon growth.

To assess later effects of chodl knockdown, we analyzed branching of motor nerves onto the myotomes in HB9:GFP transgenic animals at 48 hpf (data not shown) and 72 hpf (Fig. 5F), when motor nerves consist of many axons from primary and secondary motor neurons. Even though the main motor nerves formed, the density of motor branches on trunk muscles was reduced compared with control morpholino-injected animals at both time points.

To determine whether this phenotype was a consequence of reduced axon growth or missing motor neurons, we followed individual CaP axons over time by coinjection of morpholino and an HB9:GFP plasmid, which randomly labels few individual motor neurons. In controls injected with the plasmid and control morpholino (n = 4 embryos), all 10 observed CaP axons had grown beyond the horizontal myoseptum at 24 hpf, reached the ventral edge of the trunk and started to branch at 48 hpf, and were still present at 72 hpf (Fig. 6G). In experimental animals (n = 6), we observed eight axons at different time points. Only one of eight CaP axons displayed the growth patterns observed in controls. Some axons were still at the level of the horizontal myoseptum at 33 hpf (three of seven axons) and only two of eight axons had reached the ventral edge of the trunk at 48 hpf. At 72 hpf, axons were still short (two of seven axons; Fig. 6G) or showed signs of degeneration, such as axon retraction, or loss of cells (four of seven axons). Thus hypoinnervation of myotomes in chodl morphants at 72 hpf was due to long-term impairment of axon growth and/or eventual degeneration.

**CaP motor axons are specifically affected at the horizontal myoseptum in chodl morphants**

Motor axons pause at the horizontal myoseptum during their growth and in the case of the CaP axon later continue to grow into the ventral myotome (Eisen et al., 1986). To determine which of the different phases of axon growth were affected by the knockdown resulting in shorter axons, we categorized axon lengths. Already at 24 hpf almost all axons had grown ventrally beyond the horizontal myoseptum. At 24 hpf (4.3%) and 33 hpf (1.7%), few axons had not reached the horizontal myoseptum in morphants. Strikingly, 34.6% of the axons had extended only to the position of the horizontal myoseptum, significantly more than in control morpholino-injected embryos (0.2%) at 24 hpf. At 33 hpf, 31.3% of the segments still showed axons at the level of the horizontal myoseptum. This was not significantly different from the proportion at 24 hpf, suggesting that almost one-third of the CaP axons were completely arrested at the horizontal myoseptum over the observation period. At 24 hpf, 54% of the axons had grown beyond the horizontal myoseptum but were not of wild-type length and only 8% appeared to be of normal length. At 33 hpf, 39% of the axons—almost five times more than at 24 hpf—were of normal length, suggesting that axons grew relatively quickly once they passed the horizontal myoseptum. Combined, this distribution of axon lengths indicates that axons reach the horizontal myoseptum similar to controls and then spend a disproportionately long time at the horizontal myoseptum to either continue growth or stop at the horizontal myoseptum (Fig. 7A,B).

To directly test this hypothesis, we visualized growth of ventral motor axons by time-lapse analysis in morpholino-injected HB9:GFP transgenic embryos (Fig. 7C,D). Results revealed that, up to 21 hpf, morphant and wild-type axons grew at comparable velocities (control: 7.1 ± 0.7 μm/h, n = 4 axons; morphant: 8.3 ± 1.2 μm/h, n = 8 axons; p = 0.54), similar to previously reported growth speeds (7.1 ± 1.3 μm/h) (Myers et al., 1986). After that time, wild-type and morphant axons slowed down at the horizontal myoseptum (growth velocity wild-type: 5.4 ± 1.3 μm/h, n = 4; morphant: 4.1 ± 0.8 μm/h, n = 6; p = 0.359). Around 24 hpf, wild-type axons continued to grow into the ventral myotome at a velocity of 9.6 ± 1.2 μm/h (n = 4), whereas morphant axons displayed two types of behaviors. Either axons stalled at the horizontal myoseptum until 27 hpf, the end of the observation period, or they resumed growth and entered the ventral myotome a short time (~1.5 h) after the wild-type axons. When morphant axons entered the ventral myotome, their growth speed (10.5 ± 2.6 μm/h; p = 0.7) was again comparable with that of wild-type axons. Both types of morphant axon behaviors resulted in significantly shorter axons when compared with controls after the horizontal myoseptum was reached (Fig. 7D). Thus, histology and in vivo time-lapse analysis showed normal growth velocity of morphant axons before and after the horizontal myoseptum was reached. However, the normal stalling period at the horizontal myoseptum was either significantly prolonged or axons were completely arrested at the horizontal myoseptum.
Overexpression of *chodl* leads to shorter motor axons and rescues knockdown effects

Next, we determined whether increasing the levels of *chodl* expression would perturb motor axon growth. After injection of mRNA transcribed *in vitro* from a bicistronic vector coding for *chodl* and GFP, we observed ubiquitous GFP expression in the embryo. In control RNA-injected embryos, 75% of the axons were of wild-type length, whereas significantly fewer axons (31%) were of wild-type length in mRNA-injected embryos (Fig. 8A, B). This result indicates that overexpression of *chodl* impairs growth in a proportion of axons and suggests that specific levels of *chodl* expression are important for optimal axon elongation.

If specific levels of *chodl* expression were necessary for correct interactions of motor axons with the horizontal myoseptum, mRNA overexpression should rescue effects of gene knockdown. Indeed, when the highly efficient start codon-directed morpholino MO3 was injected at a concentration of 0.5 μM, together with control RNA, only 16.5% of the axons were of wild-type length. In contrast, coinjection with *chodl* mRNA led to approximately three times more axons of wild-type length (57%), which was statistically highly significant (Fig. 8C, D). It is unlikely that the morpholino inadvertently interacted directly with the injected RNA, since a sequence of only 5 bases of the morpholino matched the sequence of the injected RNA and morpholinos become ineffective when as few as 5 of their 20–21 bases are not matched to the target RNA (Eisen and Smith, 2008). Combined, these results indicate that levels of *chodl* expression are critical for correct interactions of motor axons with the horizontal myoseptum.

**Discussion**

Here, we used a novel expression profiling paradigm to find factors expressed by motor neurons necessary for correct axon growth. We find the C-type lectin *chodl* as crucial for interactions of motor axons with the horizontal myoseptum, an important navigational choice point. Our study is the first to demonstrate a developmental function of *chodl*, which has been implicated in SMA (Zhang et al., 2008; Bäumer et al., 2009).

**chodl** has a specific role in intermediate target recognition

*Chodl* knockdown leads to a very specific phenotype in motor neurons. Motor axons exit the spinal cord and approach the horizontal myoseptum correctly and at normal velocity, as determined in histological preparations and by time-lapse video analysis. Axon growth was even unimpeded for those growth
cones that were able to pass the horizontal myoseptum. It was only in the position of this choice point that axons stalled for a disproportionately long time or stopped altogether, supporting that *chodl* is necessary for axons to correctly interpret guidance cues in the horizontal myoseptum. The fact that overexpression of *chodl* induced a similar phenotype as knockdown supports that the level of *chodl* expression needs to be optimal for efficient interactions with the horizontal myoseptum. Similarly, loss of function and gain of function for the ECM component collagen XIXa1 (*colXIX*) (also known as *stumpy*) at the horizontal myoseptum both elicit the same phenotype—shorter motor axons (Hilario et al., 2010). Although motor nerves eventually form in *chodl* morphants, the observation that muscle innervation is still sparse at later time points of development indicates that *chodl* might be important not only at the horizontal myoseptum choice point, but at choice points or intermediate targets that exist at more distal positions along motor axon pathways (Beattie, 2000). The observation in single CaP axon tracing that some axons that topoed from another C-type lectin to be implicated in axon pathfinding in vertebrates. In *C. elegans* another C-type lectin, CLEC-38, has been shown to be involved in dorsal axon guidance (Kulkarni et al., 2008).

**What are the potential ligands of Chodl?**

The *chodl* structure carries the hallmarks of an ECM receptor, with a signal peptide, a transmembrane domain, and a C-type lectin domain, shown to interact with ECM molecules (Lundell et al., 2004). Interestingly, the phenotypes of *chodl* morphants and mutants for the ECM molecule *colXIX* at the horizontal myoseptum are quite similar (Beattie et al., 2000; Hilario et al., 2010). Both conditions show normal growth of axons along the common pathway, stalling and stopping of axons at the horizontal myoseptum, impaired growth of the CaP and MiP axon, and reduced innervation of the musculature at later developmental stages. However, there need not be direct physical interactions between Chodl and ColXIX, as the ECM at the horizontal myoseptum is complex and ColXIX could simply anchor other potential interaction partners to the horizontal myoseptum. For example, Tenascin-C (Schweitzer et al., 2005) and chondroitin sulfates (Bernhardt and Schachner, 2000) are accumulated at the horizontal myoseptum and play a role in motor axon growth. In the mutant for the muscle-specific tyrosine kinase *unplugged*, in which deposition of Tenasin-C and chondroitin sulfates is defective, motor axons make inappropriate pathway decisions at the horizontal myoseptum (Zhang et al., 2004; Schweitzer et al., 2005). Interestingly, C-type lectin domains, such as that in Chodl, have been shown to interact with Tenasin-C (Lundell et al., 2004). Moreover, enzymatic modification of glycosylation of the myotome-derived type XVIII collagen is also important for motor axon extension (Schneider and Granato, 2006). Finally, the *topped* mutation represents an unknown muscle-derived activity (Rodino-Klapac and Beattie, 2004), which also leads to stalling of CaP axons at the horizontal myoseptum. While it is obvious that motor axons encounter a complex ECM at the horizontal myoseptum, the identity of specific interaction partners of *chodl* are presently unclear.

**Possible connection of chodl to SMA**

We show here that *chodl* is evolutionarily highly conserved, with an amino acid identity of >92% across vertebrate classes. *chodl* is specifically expressed in fast motor neurons in mice (Enjin et al., 2010). SMA is caused by reduced levels of the "survival of motor neurons" (SMN) genes, which are involved in RNA splicing among other functions (for recent review, see Sleigh et al., 2011). Using exon profiling in mouse models of SMA, specific isoform changes for *chodl* have been found already at early symptomatic stages, whereas most genes were dysregulated only at late symptomatic stages (Zhang et al., 2008; Bäumer et al., 2009). Reduced expression of SMN leads to shorter mouse motor axons in *vitro* (Rossoll et al., 2003), and one of the phenotypes in developing

Figure 8. *chodl* overexpression affects axon growth and rescues morphants. Lateral trunk views of HB9:GFP transgenic embryos are shown (orientation as in Fig. 1A; short axons are indicated by arrowheads; categories in B and D are the same as in Fig. 7). **A, B,** Injection of *chodl* mRNA alone induces shorter CaP axons. **C, D,** Shorter axons induced by *chodl* MO3 (0.5 μM; C, arrowheads) are rescued by *chodl* RNA. *p < 0.05; ***p < 0.001. Scale bar: C, 50 μm. Error bars indicate SEM.
ever, studies in other mouse SMA models do not find abnormal
show signs of degeneration at 72 hpf (Beattie et al., 2000). How-
showing a similar phenotype as our chodl morphants, CaP axons
that are permanently stalled at the horizontal myoseptum also
show signs of degeneration at 72 hpf (Beattie et al., 2000). How-
however, studies in other mouse SMA models do not find abnormal
development of motor axons, but degeneration of axons once
axonal connections are established (McGovern et al., 2008; Murray
et al., 2010). Hence, chodl could have roles in axon mainte-
nance as well as pathfinding.

Expression profiling of HB9:GFP+ cells from
DN-CLIM-injected embryos reveals genes potentially
involved in motor axon differentiation
Our gene array expression profiling has revealed three genes that
are specifically expressed in motor neurons, and we demonstrate a role in axon growth for one of these. This supports that this
screening approach identifies axonal factors that may be involved in
motor axon growth. In our approach, we reasoned that HB9:GFP+ neurons may retain expression of genes needed to maintain motor neuron identity to a certain degree and general axon growth after DN-
CLIM treatment. Thus, genes involved in motor axon navigation should be enriched in the list of downregulated genes after DN-
CLIM treatment. The fact that many HB9:GFP+ cells retained HB9 and Islet-1/-2 immunoreactivity and only few acquire interneuron marker expression supported this notion. However, we confirm here that some motor neurons acquire the interneuron marker GABA when LIM-HD signaling is blocked (Segawa et al., 2002), and we show that many motor neurons lose expression of the mature motor neuron marker ChAT and fewer cells expressed GFP in DN-CLIM-injected embryos. Given that combi-
natorial expression of LIM-HD factors controls motor neuron fate in vertebrates (Tsujida et al., 1994; Pfaff et al., 1996), includ-
ing zebrafish (Inoue et al., 1994; Appel et al., 1995; Toku-
moto et al., 1995; Hutchinson and Eisen, 2006; Hutchinson et al., 2007), it is likely that HB9:GFP+ neurons lose some aspects of their motor neuron identity under DN-CLIM treatment.

Nevertheless, using our approach, we identified chodl, tcalc1, and calca with motor neuron-specific expression, which are downstream of the LIM-HD regulatory network. The fact that chodl is expressed very early during motor neuron differentiation supports relatively proximal regulation of the gene by the LIM-HD network. Although the promoter regions of all three genes contain putative recognition motifs for LIM-HD (data not shown), it is presently unclear whether direct regulation occurs. Future research will have to show whether tcalc1, coding for the neuropeptides substance P/neurokinin A (Nawa et al., 1984), and calca, coding for calcitonin and the calcitonin–related neuropeptide (Amara et al., 1982), have specific roles in motor axon navigation or synapse formation.

We conclude that our newly designed expression profiling approach to motor axon pathfinding has revealed the LIM-HD
regulated C-type lectin chodl as pivotal in choice point interac-
tions for growing motor axons. Discovering the genes involved in
axonal differentiation and analyzing their function in zebrafish may ultimately lead to a better understanding of motor neuron
diseases such as SMA.

References
RNA processing in calcitonin gene expression generates mRNAs encod-
Motoneuron fate specification revealed by patterned LIM homeobox
Bae YK, Shimizu T, Muraoaka O, Yabe Y, Hirata T, Nojima H, Hirano T, Hibi
Expr Patterns 4:481–486.
and GABAergic fates of multiple spinal interneurons. Dev Biol
Baumé D, Lee S, Nicholson G, Davies IJ, Parkinson NJ, Murray LM, Gilling-
encoding a late feature of pathology in a mouse model of spinal muscular
Beattie CE, Melancon E, Eisen JS (2000) Mutations in the stumpy gene re-
veal intermediate targets for zebrafish motor axons. Development
Bernhardt RR, Schachner M (2000) Chondroitin sulfates affect the forma-
tion of the segmental motor nerves in zebrafish embryos. Dev Biol
Bhati M, Lee C, Nancarrow AL, Lee M, Craig VJ, Bach I, Issa JM, Mackay JP,
Matthews IM (2008) Implementing the LIM code: the structural basis
for cell-type-specific assembly of LIM-homeodomain complexes. EMBO J
Perspect Biol 2:a001735.
Draper BW, Morcos PA, Kimmel CB (2001) Inhibition of zebrafish fgf8
pre-mRNA splicing with morpholino oligos: a quantifiable method for
Eisen JS, Smith JC (2008) Controlling morpholino experiments: don’t stop
Eisen JS, Myers PZ, Westerfield M (1986) Pathway selection by growth
cones of identified motoneurones in live zebrafish embryos. Nature
Enjin A, Rabe N, Nakanishi ST, Valtzstadt A, Gezelius H, Memic F, Lind M,
Hjalt T, Tourtellotte WG, Bruder C, Eichele G, Whelan PJ, Kullander K
(2010) Identification of novel spinal cholinergic genetic subtypes dis-
close Chodl and Pitx2 as markers for fast motor neurons and partition-
Feldner J, Becker T, Goishi K, Schweitzer J, Lee P, Schachner M, Klagsbrun M,
Becker CG (2005) Neuregulin-1α is involved in trunk motor axon out-
Feldner J, Reimer MM, Schweitzer J, Wendik B, Meyer D, Becker T, Becker
CG (2007) PlexinA3 restricts spinal exit points and branching of trunk
Flanagan-Steet H, Fox MA, Meyer D, Sanes JR (2005) Neuromuscular syn-
apses can form in vivo by incorporation of initially aneural postsynaptic
Gould TW, Oppenheim RW (2011) Motor neuron trophic factors: thera-
Güngör C, Taniguchi-Ishigaki N, Ma H, Draper BW, Liu L, Ong ES, Evans RM


